{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:55:52Z","timestamp":1793969752046,"version":"4.8.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T00:00:00Z","timestamp":1735603200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.euo.2024.12.015","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T16:06:00Z","timestamp":1738598760000},"page":"763-773","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Two-fraction Versus Five-fraction Stereotactic Body Radiotherapy for Intermediate-risk Prostate Cancer: The TOFFEE Meta-analysis of Individual Patient Data from Four Prospective Trials"],"prefix":"10.1016","volume":"8","author":[{"given":"Cristian","family":"Udovicich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Detsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Morton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Szumacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Lin","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Vesprini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wee Loon","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananth","family":"Ravi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merrylee","family":"McGuffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Mamedov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Deabreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Kulasingham-Poon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Loblaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2024.12.015_b0005","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.37165","article-title":"Differential use of radiotherapy fractionation regimens in prostate cancer","volume":"6","author":"Qureshy","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.euo.2024.12.015_b0010","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2024.12.015_b0015","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer","volume":"391","author":"van As","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2024.12.015_b0020","unstructured":"National Comprehensive Cancer Network. Prostate cancer (version 4.2024). Plymouth Meeting, PA: NCCN; 2024."},{"key":"10.1016\/j.euo.2024.12.015_b0025","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1007\/s00345-023-04663-x","article-title":"The march toward single-fraction stereotactic body radiotherapy for localized prostate cancer\u2014quo vadimus?","volume":"41","author":"Ong","year":"2023","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2024.12.015_b0030","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.euo.2018.06.013","article-title":"Phase 2 multicenter trial of heterogeneous-dosing stereotactic body radiotherapy for low- and intermediate-risk prostate cancer: 5-year outcomes","volume":"1","author":"Fuller","year":"2018","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2024.12.015_b0035","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ijrobp.2010.10.026","article-title":"Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response","volume":"82","author":"Jabbari","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.euo.2024.12.015_b0040","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1748-717X-8-84","article-title":"Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results","volume":"8","author":"Aluwini","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.euo.2024.12.015_b0045","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13014-022-02037-y","article-title":"A phase II trial of stereotactic body radiotherapy in 4 fractions for patients with localized prostate cancer","volume":"17","author":"Kawakami","year":"2022","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.euo.2024.12.015_b0050","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.radonc.2015.12.020","article-title":"Dose-escalation of five-fraction SABR in prostate cancer: toxicity comparison of two prospective trials","volume":"118","author":"Musunuru","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.euo.2024.12.015_b0055","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.radonc.2018.03.005","article-title":"Dose escalation for prostate stereotactic ablative radiotherapy (SABR): late outcomes from two prospective clinical trials","volume":"127","author":"Alayed","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.euo.2024.12.015_b0060","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.radonc.2020.04.039","article-title":"Accelerating prostate stereotactic ablative body radiotherapy: efficacy and toxicity of a randomized phase II study of 11 versus 29 days overall treatment time (PATRIOT)","volume":"149","author":"Alayed","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.euo.2024.12.015_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109864","article-title":"Dosimetric correlates of toxicities and quality of life following two-fraction stereotactic ablative radiotherapy (SABR) for prostate cancer","volume":"188","author":"Ong","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.euo.2024.12.015_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109503","article-title":"Two-fraction stereotactic ablative radiotherapy with simultaneous boost to MRI-defined dominant intra-prostatic lesion\u2014results from the 2SMART phase 2 trial","volume":"181","author":"Ong","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.euo.2024.12.015_b0075","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.ijrobp.2023.06.250","article-title":"To boost or not to boost: pooled analyses from 2-fraction SABR trials for localized prostate cancer","volume":"117","author":"Ong","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.euo.2024.12.015_b0080","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13014-015-0426-4","article-title":"Clinical evaluation of an endorectal immobilization system for use in prostate hypofractionated stereotactic ablative body radiotherapy (SABR)","volume":"10","author":"Nicolae","year":"2015","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.euo.2024.12.015_b0085","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.clon.2021.11.004","article-title":"Four-year prostate-specific antigen response rate as a predictive measure in intermediate-risk prostate cancer treated with ablative therapies: the SPRAT analysis","volume":"34","author":"Glicksman","year":"2022","journal-title":"Clin Oncol"},{"key":"10.1016\/j.euo.2024.12.015_b0090","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1001\/jamaoncol.2021.0039","article-title":"Safety and efficacy of virtual prostatectomy with single-dose radiotherapy in patients with intermediate-risk prostate cancer: results from the PROSINT phase 2 randomized clinical trial","volume":"7","author":"Greco","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euo.2024.12.015_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110181","article-title":"ONE SHOT\u2014single shot radiotherapy for localized prostate cancer: 18-month results of a single arm, multicenter phase I\/II trial","volume":"194","author":"Zilli","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.euo.2024.12.015_b0100","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.ijrobp.2024.06.030","article-title":"Ablative Radiation Therapy for Unfavorable Prostate Tumors (ABRUPT): preliminary analysis of toxicity and quality of life from a prospective study","volume":"120","author":"Arcangeli","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.euo.2024.12.015_b0105","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ijrobp.2023.09.032","article-title":"Interim toxicity analysis from the randomized HERMES trial of 2- and 5-fraction magnetic resonance imaging-guided adaptive prostate radiation therapy","volume":"118","author":"Westley","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.euo.2024.12.015_b0110","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.ijrobp.2024.06.038","article-title":"Acute toxicity and early prostate specific antigen response after two-fraction stereotactic radiation therapy for localized prostate cancer using peri-rectal spacing\u2014initial report of the SABR-Dual trial","volume":"120","author":"Fredman","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.euo.2024.12.015_b0115","unstructured":"Sunnybrook Health Sciences Centre. Improving sexual quality of life - a phase 2 randomized controlled trial of two vs five stereotactic MRI-guided ablative radiotherapy treatments for prostate cancer (iSMART). https:\/\/clinicaltrials.gov\/study\/NCT05600400."},{"key":"10.1016\/j.euo.2024.12.015_b0120","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1186\/s12885-023-11430-z","article-title":"A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT)","volume":"23","author":"Wolfe","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.euo.2024.12.015_b0125","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/jamaoncol.2022.6558","article-title":"Magnetic resonance imaging-guided vs computed tomography-guided stereotactic body radiotherapy for prostate cancer: the MIRAGE randomized clinical trial","volume":"9","author":"Kishan","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euo.2024.12.015_b0130","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.prro.2021.06.009","article-title":"Moving unfavorable small-bowel anatomy away from the prostate to optimize radiation therapy plans with the GU-Lok","volume":"11","author":"Glicksman","year":"2021","journal-title":"Pract Radiat Oncol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931124002980?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931124002980?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T12:55:31Z","timestamp":1748436931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931124002980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2588931124002980"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2024.12.015","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Two-fraction Versus Five-fraction Stereotactic Body Radiotherapy for Intermediate-risk Prostate Cancer: The TOFFEE Meta-analysis of Individual Patient Data from Four Prospective Trials","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2024.12.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}